Breaking News
July 21, 2018 - Intervention program that includes a personalized app could benefit teens with suicidal thoughts
July 21, 2018 - Researchers identify new compound that protects against neurodegeneration
July 21, 2018 - Gene therapy may hold potential to treat people with spinal cord injuries
July 21, 2018 - FDA Approves Nivestym (filgrastim-aafi), a Biosimilar to Neupogen
July 21, 2018 - Surgeons have substantial impact on genetic testing in breast cancer patients who need it
July 21, 2018 - Species diversity can have positive and negative impacts on disease transmission
July 21, 2018 - Genome research suggests presence of enteric fever in medieval Europe
July 21, 2018 - Risk of Sensory Deficits Drops With Rising Gestational Age
July 21, 2018 - Mum’s sleep matters—the effect of sleep on an unborn baby
July 21, 2018 - UC San Diego researchers awarded two grants for investigating stem cell-based therapies
July 21, 2018 - Cellular ‘garbage disposal’ may actually work on some of the proteins to neuronal development
July 21, 2018 - More Pregnant Women Having Heart Attacks
July 21, 2018 - Acne Breakouts | NIH News in Health
July 21, 2018 - Change health messaging to focus on potential impact to help stop the next pandemic
July 21, 2018 - Frailty associated with poor survival rates in young heart patients
July 21, 2018 - New discovery could save millions of lives from fatal fungal infections
July 21, 2018 - OBD presents latest data on the use of EpiSwitch™ in predicting patient response to immunotherapy and identifying lymphoma subtypes
July 21, 2018 - Childhood adversity increases susceptibility to addiction via immune response
July 21, 2018 - Scientists identify potential target for the treatment of binge eating
July 21, 2018 - Whole-brain LIPUS therapy improves cognitive dysfunction in mice simulating dementia, Alzheimer’s
July 21, 2018 - Digital media use raising risk of ADHD symptoms among the young
July 21, 2018 - Phase 3 study of tanezumab in patients with osteoarthritis pain meets all three co-primary endpoints
July 21, 2018 - Restoring mitochondrial function to reverse aging-related skin wrinkles, hair loss in mice
July 21, 2018 - SP PennTech introduces RW-500 rotary vial washer for biotech, pharmaceutical applications
July 21, 2018 - Researchers to study molecular mechanisms behind susceptibility of males to autism
July 21, 2018 - Fourth Published Clinical Trial Confirms Long-Term Safety of Niagen Supplementation at High Doses and Shows Potential for Improvement in Liver Health
July 21, 2018 - Study examines effects of a two-day intermittent calorie restriction diet for patients with type 2 diabetes
July 21, 2018 - Greening vacant urban land reduces feelings of depression for surrounding residents
July 21, 2018 - Parents say intense gun violence in PG-13 movies appropriate for teens 15 and older
July 21, 2018 - Collaborative study to assess effects of exercise training for cognitive deficits in MS
July 21, 2018 - FAU researchers find possible cause of Parkinson’s disease in the patients’ immune system
July 21, 2018 - Protective qualities of ‘good cholesterol’ reduce after menopause
July 21, 2018 - Researchers develop new way to uncover hidden breast cancer tumors
July 21, 2018 - FDA approves first drug for treatment of adult AML patients with specific genetic mutation
July 21, 2018 - Top AI companies join hands to discover novel drugs for DMD
July 21, 2018 - Ferring announces FDA approval of ZOMACTON for injection in four new pediatric indications
July 20, 2018 - Researchers design proteins that can self-assemble into complex structures
July 20, 2018 - AVITA Medical expands management team to support launch of RECELL device to treat burns
July 20, 2018 - FDA Approves Tibsovo (ivosidenib) for Relapsed or Refractory Acute Myeloid Leukemia with an IDH1 Mutation
July 20, 2018 - Developmental screening and surveillance rates remain low, new study suggests
July 20, 2018 - TGen opens tissue donation portal to advance DIPG research
July 20, 2018 - Health impact of highly processed summertime staples
July 20, 2018 - Exergaming can improve health in overweight and obese children, study shows
July 20, 2018 - Postmenopausal factors may impact heart-protective qualities of ‘good cholesterol’
July 20, 2018 - MRI and blood test combination results in improved prostate cancer diagnosis
July 20, 2018 - Update Health Professional and Consumer on Recent Recalled Products
July 20, 2018 - Researchers trace Parkinson’s damage in the heart
July 20, 2018 - Wearable device designed to measure cortisol in sweat
July 20, 2018 - Scientists demonstrate a new regulation mechanism for skeletal muscles
July 20, 2018 - Exposure to mobile phone radiation may negatively impact memory performance in adolescents
July 20, 2018 - SUSU scientists find alternative method to treat post-traumatic stress disorder syndrome
July 20, 2018 - Gestational diabetes may increase offspring’s heart disease risk
July 20, 2018 - New vaccine could protect unborn babies from Zika virus
July 20, 2018 - Researchers find high mercury and methylmercury concentrations in traditional Tibetan medicine
July 20, 2018 - Brief Safety Plan Intervention in ER Can Cut Suicidal Behavior
July 20, 2018 - The Mount Sinai Hospital receives accreditation as geriatric emergency department
July 20, 2018 - Toward a better understanding of Parkinson’s disease
July 20, 2018 - Med school communications office wins four national awards | News Center
July 20, 2018 - Professional baseball players with faster hand-eye coordination may have better batting performance
July 20, 2018 - Study looks into mechanisms that control sleep and wakefulness
July 20, 2018 - Scientists identify melanoma biomarkers that could help tailor immunotherapy treatments
July 20, 2018 - Research reveals long-term efficacy of drug used to treat common cause of kidney failure
July 20, 2018 - Timing of dinner associated with breast and prostate cancer risks
July 20, 2018 - Health Tip: Performing the Heimlich Maneuver
July 20, 2018 - Nearly all adolescents have eating, activity or weight-related issues
July 20, 2018 - Sage launches new web-based tool that helps explore curated genomic analyses of Alzheimer’s
July 20, 2018 - High-performance porous polymeric material for chromatography applications
July 20, 2018 - New molecule shows great promise for future treatment of many cancers
July 20, 2018 - New research project investigates alternative treatments for eye infections
July 20, 2018 - Immune T cells are built to react as fast as possible, shows study
July 20, 2018 - ZHX2 protein could offer a new treatment strategy for kidney cancer
July 20, 2018 - EKF’s Quo-Lab POC HbA1c analyzer meets international quality targets for diabetes testing
July 20, 2018 - Health burdens of very high risk drinking are potentially large, study reveals
July 20, 2018 - Using miniature drug-filled nanocarriers to target headaches and tumors
July 20, 2018 - Researchers uncover cause for progression of prostate cancer to incurable stage
July 20, 2018 - Studies highlight issues regarding black lung, opioid overdose, police violence and more
July 20, 2018 - AbbVie submits supplemental NDA to FDA for venetoclax to treat acute myeloid leukemia
July 20, 2018 - Researchers are one step closer to developing eye drops to treat age-related macular degeneration (AMD)
July 20, 2018 - Patients maintain muscle mass five years after surgically induced weight loss
July 20, 2018 - AMSBIO introduces new, powerful CRISPR/Cas9 gene editing kits
New Guidelines Address Use of Blood Thinners During Bypass Surgery

New Guidelines Address Use of Blood Thinners During Bypass Surgery

image_pdfDownload PDFimage_print

Action Points

  • The first-ever clinical practice guidelines aimed at standardizing the use of blood thinners during heart surgery emphasize optimal heparin dosing during bypass, identification of contraindications to heparin use and heparin alternatives, and reversal of anticoagulation.
  • For patients with a diagnosis of heparin-induced thrombocytopenia and who are in need of an urgent operation requiring cardiopulmonary bypass (CPB), anticoagulation with bivalirudin is a reasonable option.

First-ever clinical practice guidelines aimed at standardizing the use of blood thinners during heart surgery emphasize optimal heparin dosing during bypass, identification of contraindications to heparin use and heparin alternatives, and reversal of anticoagulation.

The guidelines, published Friday afternoon, were developed by leaders in the field representing the Society of Thoracic Surgeons (STS), the Society of Cardiovascular Anesthesiologists (SCA), and the American Society of ExtraCorporeal Technology (AmSECT).

The document was published concurrently in the journals Annals of Thoracic Surgery, Anesthesia & Analgesia, and the Journal of Extra Corporeal Technology.

“It is our hope that these guidelines will help clinicians practice consistent and safe anticoagulation and that there will be more standardization in practice,” said the lead author, Linda-Shore-Lesserson, MD, director of Cardiovascular Anesthesiology at North Shore University Hospital in Manhasset, New York. “Surgeons, anesthesiologists, and perfusionists will better appreciate the science behind the practices that they conduct every day.”

The joint writing group noted that even though cardiopulmonary bypass (CPB) surgery has been widely performed for more than 50 years, succinct guidelines on the delivery of heparin and other blood thinners have not existed.

“For this and other reasons, there is enormous practice variability relating to the use and dosing of heparin, monitoring heparin anticoagulation, reversal of anticoagulation, and the use of alternative anticoagulants,” the authors wrote.

The guidelines were derived based on evaluation of close to 100 recent, highly cited studies, identified through PubMed.

The writing group stressed that there is, as yet, no ideal anticoagulation strategy for cardiac surgery with CPB in patients who cannot take heparin: “Heparin and protamine remain the gold standard for anticoagulation therapy. A small subset of patients requires heparin alternatives for the conduct of CPB. Bivalirudin seems to offer the safest heparin alternative in this setting.”

Despite bivalirudin’s short half-life of approximately 25 minutes, episodes of uncontrolled bleeding do occur, the authors noted.

“Only anecdotal experience is available to address coagulopathy in cases of bivalirudin-related hemorrhage. Consensus suggests that a multifaceted approach offers the best chance of successful hemorrhage control for these patients. Recombinant activated factor VII may be an important part of hemorrhage control, but other interventions including modified ultrafiltration, hemodialysis, and clotting factor replacement are also advocated.”

Shore-Lesserson explained that there is still a lack of definitive studies dealing with various aspects of CPB anticoagulation, especially in the area of alternative drugs to heparin. And while heparin and protamine remain the gold standard for CPB, she said, they are not perfect.

She and her co-authors called for prospective scientific trials and meta-analyses to expand the evidence base regarding anticoagulation therapy for cardiopulmonary bypass.

Specific guidelines related to heparin contraindication and alternatives include the following:

  • Clinical scoring estimates that use a fall in platelet count greater than 50% or a thrombotic event between 5 and 14 days after a heparin exposure can be used to determine whether a heparin-platelet antibody test should be performed to diagnose heparin-induced thrombocytopenia (HIT). (Class IIa Recommendation, Level of Evidence B)
  • Serum tests that include functional testing with serotonin release assay (SRA) or heparin-induced platelet activation (HIPA) can be beneficial in identifying patients with HIT who have a history of thrombocytopenia, and elevated clinical HIT risk scores, when platelet factor 4 (PF4)–heparin antibody testing is inconclusive (weakly positive) for HIT. (Class IIa Recommendation, Level of Evidence C)
  • For patients who are seropositive for heparin-platelet antibodies or have a recent history of HIT, it is reasonable to delay elective cardiac operations requiring CPB until a patient’s functional test or antigenic (antibody) assay is negative, with the expectation that heparin anticoagulation therapy for CPB is likely to be safe and effective. (Class IIa Recommendation, Level of Evidence C)
  • For patients with a diagnosis of HIT and who are in need of an urgent operation requiring CPB, anticoagulation with bivalirudin is a reasonable option. (Class IIa Recommendation, Level of Evidence B)
  • In patients with significant renal dysfunction who are seropositive for HIT and require urgent operation requiring CPB, use of plasmapheresis, argatroban, or heparin with antiplatelet agents (such as tirofiban, ilioprost) may be considered, with the understanding that there are increased risks of bleeding with these interventions. (Class IIb Recommendation, Level of Evidence C)

Guidelines related to reversal of anticoagulation during CPB include:

  • Protamine dosing for heparin reversal: It can be beneficial to calculate the protamine reversal dose based on a titration to existing heparin in the blood, as this technique has been associated with reduced bleeding and blood transfusion. (Class IIa Recommendation, Level of Evidence B)
  • Protamine overdose: It is reasonable to limit the ratio of protamine/heparin to less than 2.6 mg protamine per 100 units heparin, because total doses above this ratio inhibit platelet function, prolong ACT, and increase the risk of bleeding. (Class IIa Recommendation, Level of Evidence C)
  • Heparin rebound: Because of the risk of heparin rebound in patients requiring high doses of heparin and with prolonged CPB times, low-dose protamine infusion (25 mg/h) for as long as 6 hours after the end of CPB may be considered as part of a multimodality blood-conservation program. (Class IIb Recommendation, Level of Evidence C)
  • Complications associated with protamine reversal of heparin after CPB: For patients at high risk for anaphylactic response to protamine who have pulmonary hypertension and circulatory collapse shortly after protamine administration, discontinuation of protamine and implementation of resuscitative measures including re-institution of CPB with adequate anticoagulation may be lifesaving. (Class I Recommendation, Level of Evidence C)
  • Anticoagulation reversal when using heparin alternatives and direct thrombin inhibitors: For patients requiring anticoagulation with bivalirudin who have excessive bleeding after CPB, a combination of modified ultrafiltration, hemodialysis, and the administration of recombinant factor VIIa with blood product replacement may be considered to improve hemostasis in these extreme situations. (Class IIb Recommendation, Level of Evidence C)

The guidelines were developed by The Society of Thoracic Surgeons, The Society of Cardiovascular Anesthesiologists, and The American Society of ExtraCorporeal Technology.

  • Reviewed by
    Robert Jasmer, MD Associate Clinical Professor of Medicine, University of California, San Francisco and Dorothy Caputo, MA, BSN, RN, Nurse Planner

2018-01-21T12:00:00-0500

Tagged with:

About author

Related Articles